On September 7, 2026, BAO PHARMA-B (02659) executed a share repurchase, spending approximately HK$1.9957 million to buy back 124,900 of its own shares.
The company disclosed that the buyback was conducted at a price range of HK$15.72 to HK$16.34 per share, according to an official filing.
This transaction marks a strategic move by the pharmaceutical firm to consolidate its equity base, utilizing available capital to purchase shares on the open market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.